REGENXBIO

Nina Hunter, Ph.D., Vice President, Corporate Strategy 

Oct. 12 | 1:45pm | UBC Ballroom 

Rockville, MD 

(NASDAQ: RGNX) 

In-person Presentation 

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a “5x’25” strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage trials or commercial products by 2025. 

www.regenxbio.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions